Edwards Lifesciences Corporation splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Transcatheter Aortic Valve Replacement at $4.5 billion, 74% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6,675
|
6,068
|
5,440
|
5,010
|
4,464
|
5,232
|
4,386
|
4,348
|
3,723
|
3,435
|
2,964
|
| Transcatheter Aortic Valve Replacement |
4,858
+11.3%
share 72.8%
|
4,488
+9.3%
share 74.0%
|
4,106
+5.8%
share 75.5%
|
3,880
+10.3%
share 77.4%
|
3,518
+2.8%
share 78.8%
|
3,422
+19.8%
share 65.4%
|
2,857
+4.4%
share 65.1%
|
2,738
+19.9%
share 63.0%
|
2,284
+12.8%
share 61.3%
|
2,024
share 58.9%
|
—
|
| Surgical |
1,078
+5.7%
share 16.2%
|
1,029
+4.9%
share 17.0%
|
981
+5.2%
share 18.0%
|
933
+4.4%
share 18.6%
|
893
+0.4%
share 20.0%
|
889
+16.7%
share 17.0%
|
762
-9.5%
share 17.4%
|
842
+10.5%
share 19.4%
|
762
-5.6%
share 20.5%
|
807
share 23.5%
|
—
|
| Critical Care |
—
|
—
|
—
|
928
+8.5%
share 18.5%
|
855
+2.4%
share 19.2%
|
835
+15.1%
share 16.0%
|
725
-2.0%
share 16.5%
|
740
+9.7%
share 17.0%
|
674
+12.2%
share 18.1%
|
601
share 17.5%
|
—
|
| Transcatheter Mitral And Tricuspid Therapies |
739
+47.8%
share 11.1%
|
551
+56.4%
share 9.1%
|
352
+78.2%
share 6.5%
|
198
+70.2%
share 3.9%
|
116
+35.0%
share 2.6%
|
86
+105.7%
share 1.6%
|
42
+48.2%
share 1.0%
|
28
+872.4%
share 0.6%
|
3
-14.7%
share 0.1%
|
3
share 0.1%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
- Listed as
- EW (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1099800
- Former names
- CVG CONTROLLED INC (until Jan 21, 2000)
Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
- Intuitive Surgical Inc ISRG
- STERIS plc STE
- Zimmer Biomet Holdings, Inc. ZBH
- Smith & Nephew PLC SNN
- Align Technology Inc ALGN
- MSA Safety Inc MSA
- Establishment Labs Holdings Inc. ESTA
- Cadre Holdings, Inc. CDRE
All 29 Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.